Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to outsmart advanced breast cancer

NCT ID NCT04538742

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is testing the safety and effectiveness of combining trastuzumab deruxtecan (T-DXd) with other cancer drugs for people with HER2-positive metastatic breast cancer. About 245 participants will receive different drug combinations to find the best doses and see if the tumors shrink or stop growing. The goal is to improve treatment options for this advanced form of breast cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

trastuzumab deruxtecan (T-DXd) combined with other anti-cancer drugs (durvalumab, paclitaxel, pertuzumab, tucatinib)

What this could lead to

If successful, this could point toward more effective combination treatments for HER2-positive metastatic breast cancer, potentially improving how long the disease is controlled.

What could go wrong

This is an early-phase trial (Phase 1b/2) with a small number of participants, so results may not apply to all patients. Combining drugs also raises the risk of side effects, and the study is not designed to prove a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer breast cancer breast carcinoma breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC BREAST CANCER

Contacts and locations

Locations

  • Research Site

    Fort Myers, Florida, 33901, United States

  • Research Site

    St. Petersburg, Florida, 33705, United States

  • Research Site

    Commack, New York, 11725, United States

  • Research Site

    Harrison, New York, 10604, United States

  • Research Site

    New York, New York, 10016, United States

  • Research Site

    New York, New York, 10065, United States

  • Research Site

    Columbus, Ohio, 43219, United States

  • Research Site

    Nashville, Tennessee, 37203, United States

  • Research Site

    Fort Worth, Texas, 76104, United States

  • Research Site

    Fairfax, Virginia, 22031, United States

  • Research Site

    Melbourne, 3000, Australia

  • Research Site

    Barretos, 14784-400, Brazil

  • Research Site

    Belo Horizonte, 30150-274, Brazil

  • Research Site

    Natal, 59075-740, Brazil

  • Research Site

    Porto Alegre, 90610-000, Brazil

  • Research Site

    Porto Alegre, 91350-200, Brazil

  • Research Site

    Rio de Janeiro, 20560-120, Brazil

  • Research Site

    São Paulo, 01317-001, Brazil

  • Research Site

    São Paulo, 04029-000, Brazil

  • Research Site

    Sorocaba, 18030-005, Brazil

  • Research Site

    Montreal, Quebec, H2X 0A9, Canada

  • Research Site

    Québec, Quebec, G1S 4L8, Canada

  • Research Site

    Toronto, M5G 2M9, Canada

  • Research Site

    Villejuif, 94805, France

  • Research Site

    München, 81675, Germany

  • Research Site

    Würzburg, 97080, Germany

  • Research Site

    Delhi, 110085, India

  • Research Site

    Gurgaon, 122001, India

  • Research Site

    Madurai, 625107, India

  • Research Site

    Mumbai, 400012, India

  • Research Site

    Bologna, 40138, Italy

  • Research Site

    Milan, 20141, Italy

  • Research Site

    Naples, 80131, Italy

  • Research Site

    Rome, 168, Italy

  • Research Site

    Bydgoszcz, 85-796, Poland

  • Research Site

    Koszalin, 75-581, Poland

  • Research Site

    Lodz, 90-242, Poland

  • Research Site

    Lublin, 20-090, Poland

  • Research Site

    Moscow, 105229, Russia

  • Research Site

    Moscow, 109240, Russia

  • Research Site

    Moscow, 111123, Russia

  • Research Site

    Moscow, 115478, Russia

  • Research Site

    Moscow, 117997, Russia

  • Research Site

    Moscow, 121205, Russia

  • Research Site

    Moscow, 143423, Russia

  • Research Site

    Saint Petersburg, 195271, Russia

  • Research Site

    Saint Petersburg, 196603, Russia

  • Research Site

    Saint Petersburg, 197758, Russia

  • Research Site

    Busan, 602-739, South Korea

  • Research Site

    Seoul, 02841, South Korea

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Seoul, 06351, South Korea

  • Research Site

    Barcelona, 08003, Spain

  • Research Site

    L'Hospitalet de Llobregat, 08908, Spain

  • Research Site

    Madrid, 28007, Spain

  • Research Site

    Madrid, 28050, Spain

  • Research Site

    Seville, 41013, Spain

  • Research Site

    Hualien City, 970, Taiwan

  • Research Site

    Tainan, 704, Taiwan

  • Research Site

    Taipei, 10048, Taiwan

  • Research Site

    Taipei, 10449, Taiwan

  • Research Site

    Taipei, 11217, Taiwan

  • Research Site

    Taipei, 114, Taiwan

  • Research Site

    Taipei, 235, Taiwan

  • Research Site

    Taoyuan City, 333, Taiwan

  • Research Site

    Ankara, 6100, Turkey (Türkiye)

  • Research Site

    Edirne, 22030, Turkey (Türkiye)

  • Research Site

    Istanbul, 34662, Turkey (Türkiye)

  • Research Site

    Istanbul, 34722, Turkey (Türkiye)

  • Research Site

    Izmir, 35100, Turkey (Türkiye)

  • Research Site

    Buckhurst Hill, IG9 5HX, United Kingdom